FATE THERAPEUTICS INC (FATE) Form 8-K — Aug 13, 2026
Fate Therapeutics reported second quarter 2026 results on August 13, 2026: revenue of $2.1 million (vs. $1.9 million a year ago), total operating expenses of $33.2 million, and a net loss of $30.2 million, or $(0.25) per share, improved from a $34.1 million loss, or $(0.29) per share, in Q2 2025. Cash, cash equivalents, and investments stood at $153.8 million as of June 30, 2026, a quarterly decrease of $21 million, and management guided to an operating runway into 2028 after cutting six-month operating expenses by $14.3 million year over year.
Key figures
- Revenue
- 2082000
- Guidance
- Operating runway into 2028 driven by improvements to the expense structure, along with $153.8 million in cash, cash equivalents, and investments
- Revenue Yoy
- up from $1.9 million in Q2 2025
- Total Assets
- 260103000
- Cash Position
- 153800000
- Ft819 dose cells
- 900000000
- Ytd opex reduction
- 14300000
- Ga expenses q2 2026
- 8829000
- Rd expenses q2 2026
- 24387000
- Quarterly cash decrease
- 21000000
- Common shares outstanding
- 116700000
- Preferred conversion ratio
- each preferred share convertible into five common shares
- Non cash stock compensation
- 3500000
- Preferred shares outstanding
- 2800000
- Reclaim ln enrollment target
- first half of 2028
- Reclaim ln planned enrollment
- approximately 53 patients
- Pre funded warrants outstanding
- 3900000
- Total operating expenses q2 2026
- 33216000
Price after filing
Close on the filing date to close N calendar days later (from $2.52). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.